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Abstract	
Next generation sequencing data from human cancers are often difficult to 
interpret within the context of tumour evolution. We developed a mathematical 
model describing the accumulation of mutations under neutral evolutionary 
dynamics and showed that 323/904 cancers (~30%) from multiple types were 
consistent with the neutral model of tumour evolution. 		
Deep sequencing of tumour samples reveals the fraction of cells that harbour 
individual mutations. These mutations are the result of replication errors 
during cell division and their frequency distribution is a consequence of each 
cancers evolutionary history. In our latest work 1 we utilised the distribution of 
mutant allele frequencies of tumors to infer how individual cancers grew.  
 
The shape of the mutant allele frequency distribution is determined by 
numerous factors, such as the growth characteristics of a tumor, the mutation 
rate per division and potentially, the presence of differentially growing sub-
clones. In particular, the occurrence of multiple sub-clones can introduce 
arbitrary complexity in the clonal composition of the tumor, making the 
interpretation of the mutant allele frequency distribution extremely difficult.  
We started from the simplest possible scenario where all cells in the tumour 
grow at the same rate, a situation where the tumour follows ‘neutral evolution’, 
which is the null model for molecular evolution2,3. Mathematically, this leads to 
a distribution of mutations that follows a power law. Given a mutation rate µ, a 
probability β that cells produce two surviving offspring and the frequency of 
mutations f, our model predicts that the cumulative number of mutations with 
a frequency greater than f, M(f), is linearly proportional to 1/f, 	 𝑀 𝑓 ~ ! ! !!.  [1] 		
Equation [1] has been described previously in the population genetics 
literature2,3, but has not to our knowledge been applied to cancer genomes.  
We tested the prediction of our model on next-generation sequencing data 
from 904 tumors of many different types. Remarkably, we found that more 
than 1/3 of all cases were consistent with this simple model.  	
Under this neutral model of tumour evolution, the frequency of a mutation in 
the tumor is a proxy for the time it occurred, as early events are at a high 
frequency, while later events remain at low frequencies. Mutational timelines 
can therefore be resolved, as can measurements of the mutation rate in 
individual cancers. Our mutation rate measurements yield rates of the order 
10-6-10-7 bp/division, and were higher than previous estimates (10-9 bp/division 
4). This is because what we measure is the ‘effective mutation rate’, µ/β. If 
there is high cell death in the tumor (low β) the true mutation rate may be 
much lower. Moreover, we note that this was one of the first attempts to 
measure mutation rates in vivo in human malignancies, whereas previous 
measurements were performed in vitro or were speculative. 
 
Deviations from the predictions of equation [1] indicate more complex growth 
patterns such as the presence of functionally distinct subclones. On-going 
clonal selection in cancer has been the traditional view of tumour evolution5. 
However, recent evidence might change this presumption. Multi-region 
profiling studies in colorectal cancer have found neutral evolution to be 
consistent with genomic data: using the diversity of methylation patterns as a 
measure of the age of a tumour, Siegmund et al6 observed “flat” clonal 
expansions where the age of samples from opposite parts of the tumour 
appeared the same, consistent with neutral evolution. More recently we 
proposed and validated a “Big Bang” model of colon cancer, where 
malignancies were characterised by numerous intermixed subclones and lack 
of stringent selection7. Our results extended these first observations of neutral 
evolution, demonstrating that neutral evolution can also explain the intra-
tumour heterogeneity seen in other cancer types. Interestingly, some cancer 
types seem more prone to neutral evolution than others, indicating that the 
cellular architecture and local microenvironmental conditions are likely 
important factors in determining the rules of tumour evolution. 
 
Our measurement of neutrality has the benefit that it only requires a single 
sample to perform, and can therefore be applied to a large amount of existing 
data. However, our approach only reveals the evolutionary dynamics within 
this sample. A ‘global’ inference of neutrality across an entire tumour requires 
multiple samples from different locations of the same tumour. In a recent 
study, Ling et al8 considered a large number of samples from a single 
hepatocellular carcinoma. They also found the dynamics to conform with a 
neutrally expanding tumor based on an estimate of the total number of 
mutations in the tumour. Future work will need to address the basis of ‘local’ 
versus ‘global’ neutrality. 		
Overall, our model predicts that neutral evolution leaves a characteristic 
signature in the allelic frequency distribution. Identifying this signature in 
cancer genomes enabled us to vastly simplify the interpretation of what 
appears inherently complex and noisy data. Consequently, our work 
demonstrates how integrating physically informed mathematical models and 
cancer genomics data can provide new and perhaps unexpected insight into 
these complex data. 
 
Recently, physicists were able to demonstrate the existence of gravitational 
waves by detecting an incredibly weak signal amidst a noisy dataset9. This 
was feasible because scientists knew a priori what the signal of a gravitational 
wave would look like thanks to Einstein’s field equations, formulated a century 
earlier. Cancer genomics at present suffers from the reverse problem: large 
quantities of data can already be generated but the underlying theory remains 
underdeveloped. What is lacking is the connection between theoretical and 
experimental frameworks that would allow us to fully interpret and evaluate 
the wealth of genomic data. Our latest work is, we hope, a first step in this 
direction. 
 
Figure 1 
Mutations and their frequency encode the history of individual tumours. (A) 
Mutations label distinct lineages and as a tumour grows, the size of these 
lineages becomes progressively smaller. Here, with one mutation per division 
and all cells growing at the same rate the 2 mutations occurring during the 
first division are each present in 50% of the population, mutations occurring 
during the final division are present in 12.5%. (B) When sequencing tumour 
biopsies we measure the frequency of mutations in the population. Neutral 
tumor evolution imprints a characteristic 1/f signature in the distribution of 
subclonal mutant allele frequencies. 			1.	 Williams,	M.	J.,	Werner,	B.,	Barnes,	C.	P.,	Graham,	T.	A.	&	Sottoriva,	A.	Identification	of	neutral	tumor	evolution	across	cancer	types.	Nature	
Genetics	(2016).	doi:10.1038/ng.3489	2.	 Durrett,	R.	Population	genetics	of	neutral	mutations	in	exponentially	growing	cancer	cell	populations.	The	Annals	of	Applied	Probability	23,	230–250	(2013).	3.	 Griffiths,	R.	C.	&	Tavaré,	S.	The	age	of	a	mutation	in	a	general	coalescent	tree.	Communications	in	Statistics.	Stochastic	Models	14,	273–295	(1998).	4.	 Jones,	S.	et	al.	Comparative	lesion	sequencing	provides	insights	into	tumor	evolution.	Proc.	Natl.	Acad.	Sci.	U.S.A.	105,	4283–4288	(2008).	5.	 Fearon,	E.	R.	&	Vogelstein,	B.	A	genetic	model	for	colorectal	tumorigenesis.	Cell	61,	759–767	(1990).	6.	 Siegmund,	K.	D.,	Marjoram,	P.,	Woo,	Y.-J.,	Tavaré,	S.	&	Shibata,	D.	Inferring	clonal	expansion	and	cancer	stem	cell	dynamics	from	DNA	methylation	patterns	in	colorectal	cancers.	Proc.	Natl.	Acad.	Sci.	U.S.A.	
106,	4828–4833	(2009).	7.	 Sottoriva,	A.	et	al.	A	Big	Bang	model	of	human	colorectal	tumor	growth.	Nature	Genetics	47,	209–216	(2015).	8.	 Ling,	S.	et	al.	Extremely	high	genetic	diversity	in	a	single	tumor	points	to	prevalence	of	non-Darwinian	cell	evolution.	Proc.	Natl.	Acad.	Sci.	
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